Q-omics provides the consensus-scored DNAAF4 profile across patient tissues and cancer cell-line models. DNAAF4 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, DNAAF4 is differentially expressed in 13, with the highest sampling consensus in KICH. Additionally, DNAAF4 RNA expression shows 19,180 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight BRCA, KICH, and UVM as cancer lineages where DNAAF4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DNAAF4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DNAAF4 survival associations across molecular data types. DNAAF4 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (6) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DNAAF4 RNA expression–survival associations across cancer types. High DNAAF4 expression shows unfavorable associations in KICH, LGG and ESCA, but favorable associations in BRCA, READ and UCEC. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for DNAAF4 RNA expression.
This table summarizes DNAAF4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 1. The strongest signals are observed in KICH for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for DNAAF4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DNAAF4 shows lower tumor expression in KICH, THCA and LUSC and higher tumor expression in STAD, BLCA and COAD. The KICH box plot shows higher DNAAF4 RNA expression in normal versus tumor tissue (log2 FC = −1.481, t-test p < 0.001).
This table shows molecular features associated with DNAAF4 in patient tissues and cancer cell lines. In patient samples, DNAAF4 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, DNAAF4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and BLOOD_Leukemia.
